ACA

NEUTRALM&A

Arcosa, Inc.

2026-08-05

Price

$145.32

+0.07%

This is the 2026-08-05 snapshot — the signals and analysis for ACA as of this single trading day.

View full ACA research hub →

Score10.5Top Tier

Signals5/8 DNA0/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.8xvs 20d avg

Analysis

Arcosa's price action is entirely dictated by its pending $150 per share all-cash acquisition by CRH, effectively transforming the stock into a merger arbitrage play. Despite missing Q2 earnings and revenue estimates today, the stock experienced immediate Institutional Absorption, perfectly aligning with the STEADY_CLIMB and PERFECT_STACK signals as buyers accumulate shares to capture the deal spread. Furthermore, the current RISK_ON macro regime, characterized by abundant liquidity and exceptionally tight credit spreads (0.78% OAS), provides high conviction that deal financing risks are virtually nonexistent.

Fired Signals

ALPHA MALESTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACK

Key Takeaways

Actionable Thesis: The stock is a high-conviction merger arbitrage play, drifting toward the $150 buyout price as institutional buyers absorb any fundamental 'noise' like today's Q2 earnings miss [1.1.1].
Key Risk: Regulatory hurdles, antitrust scrutiny, or a sudden widening of credit spreads that could jeopardize the pending CRH acquisition.
What to Watch: The September 4th shareholder vote and the $144.65 technical line-in-the-sand, which serves as a proxy for deal confidence.

← Back to 2026-08-05 View Full ACA History →Yahoo Finance &nearr;